HC Wainwright & Co. Reiterates Buy on Jazz Pharmaceuticals, Maintains $200 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Oren Livnat has reiterated a Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ), maintaining a $200 price target on the stock.

May 03, 2024 | 7:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jazz Pharmaceuticals receives a reiterated Buy rating and a $200 price target from HC Wainwright & Co.
The reiteration of a Buy rating and a substantial price target of $200 by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence among investors and could positively influence Jazz Pharmaceuticals' stock price in the short term. Analyst ratings, especially from well-regarded firms, often have a significant impact on how stocks are perceived in the market, potentially leading to price movements.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100